Dozens of branded peptide storefronts compete online, each with its own logo and tone. Much of the chemistry behind them comes from a small pool of contract manufacturers. Knowing how that supply chain works won't tell you a vendor is trustworthy. It does tell you what to ask before you buy.
How the supply chain is structured
Pharmaceutical-grade peptide synthesis takes real capital: solid-phase peptide synthesizers, HPLC purification columns, lyophilizers, and analytical instrumentation. Only a handful of companies operate at that level worldwide. Bachem (Switzerland) and PolyPeptide Group (multiple sites) are among the publicly documented large-scale contract manufacturers supplying active pharmaceutical ingredients to licensed drug makers. Industry coverage commonly names the two as the largest peptide CDMOs by market share. Below that tier is a broader layer of bulk API suppliers, mostly in China and India, that sell crude or purified peptide powder to anyone willing to place a minimum order.
A white-label arrangement is what happens next. A downstream company buys bulk peptide, repackages it under its own brand, and sells it to end customers. That vendor might add lyophilization, fill vials, attach its own certificate of analysis (COA), and build a website. None of that necessarily changes what is inside the vial.
Private-label and dropship models
Private-label vendors go a step past simple rebranding. They may specify a house formulation, a particular salt form, concentration, or excipient blend, that differentiates the product on paper even when the API comes from the same upstream supplier as a competitor's. Dropship models are thinner. The vendor holds no inventory and routes orders straight to a fulfillment center, sometimes one run by the same bulk supplier. Here the vendor's main contribution is the website and the customer relationship, not any physical handling of the product.
None of this is inherently fraudulent. Repackaging and private-label manufacturing are routine across consumer goods. The specific worry with research peptides is that quality-control accountability can fracture at each hand-off. A COA from the upstream supplier reflects the batch as it left that facility. What happens during shipping, storage, repackaging, and re-testing, or whether re-testing happens at all, is a separate question.
| Model | Who holds inventory | Who issues COA | Re-tested independently? |
|---|---|---|---|
| Direct manufacturer | Manufacturer | Manufacturer | Sometimes (in-house) |
| White-label reseller | Reseller | Reseller (may rely on supplier COA) | Varies widely |
| Dropship reseller | Upstream fulfiller | Often supplier-issued | Rarely |
What independent testing reveals
Third-party lab testing has repeatedly found gaps between label claims and measured content across vendors that nominally sell the same compound. The testing comes from facilities like Janoshik Analytical (an independent laboratory in Prague, Czech Republic) or through services that aggregate results, including Finnrick, Peptigrity, VialAudit, and PeptideBenchmark. As of mid-2026, Finnrick reported results spanning roughly 8,000 samples drawn from more than 200 vendors, scored on an A–E scale. Since many of those vendors share upstream suppliers, the variation often comes down to storage, handling, or skipped re-testing after repackaging rather than the original synthesis.
The wider literature documents what that variation costs. A Belgian market analysis of grey-market peptides, reported in trade and clinical coverage, found products containing anywhere from roughly 10% to 90% less active ingredient than labeled, alongside contamination findings. The label on an unregulated vial is not evidence of its contents.
A few questions serve buyers better than the brand name. Does the vendor publish a COA from an independent, named laboratory? Is the test date recent relative to the batch? Does the COA report both identity (confirming the correct peptide sequence, typically by mass spectrometry) and purity (typically by HPLC)? A COA from the vendor's own in-house team, or one that just reproduces the upstream supplier's document, carries less weight than one from a named third-party laboratory with a verifiable report number.
Research peptides sold by online vendors in this market are sold for research use and are not approved for human consumption by regulatory bodies such as the FDA or EMA. Because of that status, the quality-control standards that govern licensed pharmaceuticals, including Good Manufacturing Practice (GMP) requirements enforced by agencies, do not automatically apply to products in this channel.
The regulatory boundary has been actively contested lately. After declaring the semaglutide and tirzepatide shortages resolved in early 2025, the FDA set enforcement deadlines that wound down large-scale compounding of those GLP-1 drugs. In 2025–2026 it proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B "bulk drug substances" list, finding no clinical need to compound them from bulk powder. That activity concerns licensed compounding pharmacies, not the research-only channel directly. But it shows how unsettled the line between approved, compounded, and "research use only" peptides remains.
Sources
- Finnrick — aggregated vendor and lot-level test data
- Janoshik Analytical — independent peptide testing laboratory
- Peptigrity — vendor reputation and testing tracking
- VialAudit — community-sourced vendor audit data
- Bachem — API Manufacturing — example of a regulated upstream contract manufacturer
- FDA — Proposed exclusion of GLP-1s from the 503B bulks list (2025) — current compounding-policy context
- FDA — Current Good Manufacturing Practice — GMP regulatory framework context